Class information for:
Level 1: INTERFERON BETA//MULTIPLE SCLEROSIS//GLATIRAMER ACETATE

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
1131 2833 37.8 81%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
207 3       MULTIPLE SCLEROSIS//MYASTHENIA GRAVIS//MULTIPLE SCLEROSIS JOURNAL 52279
58 2             MULTIPLE SCLEROSIS//MULTIPLE SCLEROSIS JOURNAL//NEUROMYELITIS OPTICA 29459
1131 1                   INTERFERON BETA//MULTIPLE SCLEROSIS//GLATIRAMER ACETATE 2833

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 INTERFERON BETA authKW 1603792 15% 35% 426
2 MULTIPLE SCLEROSIS authKW 1078324 51% 7% 1437
3 GLATIRAMER ACETATE authKW 702512 6% 39% 169
4 INTERFERON BETA 1B authKW 564145 3% 62% 85
5 INTERFERON BETA 1A authKW 503500 3% 56% 84
6 DISEASE MODIFYING THERAPY authKW 374209 3% 37% 93
7 BETA INTERFERON authKW 264550 2% 42% 58
8 RELAPSING REMITTING MULTIPLE SCLEROSIS authKW 201847 3% 26% 71
9 MULTIPLE SCLEROSIS JOURNAL journal 197213 7% 9% 207
10 MITOXANTRONE authKW 182552 4% 13% 127

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Clinical Neurology 57366 61% 0% 1736
2 Neurosciences 7341 31% 0% 872
3 Immunology 1110 11% 0% 316
4 Psychiatry 1002 8% 0% 221
5 Pharmacology & Pharmacy 781 12% 0% 343
6 Medicine, General & Internal 718 9% 0% 253
7 Health Care Sciences & Services 655 4% 0% 104
8 Health Policy & Services 297 2% 0% 55
9 Medicine, Research & Experimental 62 3% 0% 85
10 Surgery 15 4% 0% 106

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 NEURO RIVE SUD 132010 0% 88% 14
2 MULTIPLE SCLEROSIS 121475 4% 10% 112
3 NEUROBIOL CLIN 111162 0% 74% 14
4 DANISH MULTIPLE SCLEROSIS 76666 1% 23% 31
5 CORINNE GOLDSMITH DICKINSON MULTIPLE SCLEROSI 76625 1% 34% 21
6 MULTIPLE SCLEROSIS CLIN 66595 1% 21% 29
7 UNITAT NEUROIMMUNOL CLIN 55907 1% 19% 28
8 MELLEN MULTIPLE SCLEROSIS TREATMENT 53535 1% 17% 30
9 NEUROL 52951 39% 0% 1107
10 MS 45085 1% 11% 39

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MULTIPLE SCLEROSIS JOURNAL 197213 7% 9% 207
2 MULTIPLE SCLEROSIS 86578 2% 12% 67
3 MULTIPLE SCLEROSIS AND RELATED DISORDERS 78667 2% 14% 52
4 NEUROLOGY 27227 8% 1% 232
5 JOURNAL OF NEUROLOGY 20589 4% 2% 108
6 JOURNAL OF NEUROIMMUNOLOGY 16214 4% 2% 101
7 EUROPEAN JOURNAL OF NEUROLOGY 13178 2% 2% 69
8 THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS 11880 0% 8% 13
9 JOURNAL OF THE NEUROLOGICAL SCIENCES 10134 3% 1% 98
10 JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 10072 2% 2% 46

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class		 LCSH search Wikipedia search
1 INTERFERON BETA 1603792 15% 35% 426 Search INTERFERON+BETA Search INTERFERON+BETA
2 MULTIPLE SCLEROSIS 1078324 51% 7% 1437 Search MULTIPLE+SCLEROSIS Search MULTIPLE+SCLEROSIS
3 GLATIRAMER ACETATE 702512 6% 39% 169 Search GLATIRAMER+ACETATE Search GLATIRAMER+ACETATE
4 INTERFERON BETA 1B 564145 3% 62% 85 Search INTERFERON+BETA+1B Search INTERFERON+BETA+1B
5 INTERFERON BETA 1A 503500 3% 56% 84 Search INTERFERON+BETA+1A Search INTERFERON+BETA+1A
6 DISEASE MODIFYING THERAPY 374209 3% 37% 93 Search DISEASE+MODIFYING+THERAPY Search DISEASE+MODIFYING+THERAPY
7 BETA INTERFERON 264550 2% 42% 58 Search BETA+INTERFERON Search BETA+INTERFERON
8 RELAPSING REMITTING MULTIPLE SCLEROSIS 201847 3% 26% 71 Search RELAPSING+REMITTING+MULTIPLE+SCLEROSIS Search RELAPSING+REMITTING+MULTIPLE+SCLEROSIS
9 MITOXANTRONE 182552 4% 13% 127 Search MITOXANTRONE Search MITOXANTRONE
10 DISEASE MODIFYING DRUGS 156700 1% 36% 40 Search DISEASE+MODIFYING+DRUGS Search DISEASE+MODIFYING+DRUGS

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 GIOVANNONI, G , SOUTHAM, E , WAUBANT, E , (2012) SYSTEMATIC REVIEW OF DISEASE-MODIFYING THERAPIES TO ASSESS UNMET NEEDS IN MULTIPLE SCLEROSIS: TOLERABILITY AND ADHERENCE.MULTIPLE SCLEROSIS JOURNAL. VOL. 18. ISSUE 7. P. 932 -946 106 69% 39
2 CARLSON, RJ , DOUCETTE, RR , KNOX, K , NAZARALI, AJ , (2015) PHARMACOGENOMICS OF INTERFERON-BETA IN MULTIPLE SCLEROSIS: WHAT HAS BEEN ACCOMPLISHED AND HOW CAN WE ENSURE FUTURE PROGRESS?.CYTOKINE & GROWTH FACTOR REVIEWS. VOL. 26. ISSUE 2. P. 249 -261 90 85% 2
3 BERTOLOTTO, A , GRANIERI, L , MARNETTO, F , VALENTINO, P , SALA, A , CAPOBIANCO, M , MALUCCHI, S , DI SAPIO, A , MALENTACCHI, M , MATTA, M , ET AL (2015) BIOLOGICAL MONITORING OF IFN-BETA THERAPY IN MULTIPLE SCLEROSIS.CYTOKINE & GROWTH FACTOR REVIEWS. VOL. 26. ISSUE 2. P. 241 -248 71 89% 6
4 BERTOLOTTO, A , (2015) EVALUATION OF THE IMPACT OF NEUTRALIZING ANTIBODIES ON IFN BETA RESPONSE.CLINICA CHIMICA ACTA. VOL. 449. ISSUE . P. 31 -36 62 98% 4
5 POLMAN, CH , BERTOLOTTO, A , DEISENHAMMER, F , GIOVANNONI, G , HARTUNG, HP , HEMMER, B , KILLESTEIN, J , MCFARLAND, HF , OGER, J , PACHNER, AR , ET AL (2010) RECOMMENDATIONS FOR CLINICAL USE OF DATA ON NEUTRALISING ANTIBODIES TO INTERFERON-BETA THERAPY IN MULTIPLE SCLEROSIS.LANCET NEUROLOGY. VOL. 9. ISSUE 7. P. 740-750 64 93% 80
6 RUDICK, RA , POLMAN, CH , (2009) CURRENT APPROACHES TO THE IDENTIFICATION AND MANAGEMENT OF BREAKTHROUGH DISEASE IN PATIENTS WITH MULTIPLE SCLEROSIS.LANCET NEUROLOGY. VOL. 8. ISSUE 6. P. 545-559 83 71% 70
7 KILLESTEIN, J , POLMAN, CH , (2011) DETERMINANTS OF INTERFERON BETA EFFICACY IN PATIENTS WITH MULTIPLE SCLEROSIS.NATURE REVIEWS NEUROLOGY. VOL. 7. ISSUE 4. P. 221-228 62 89% 43
8 BALASA, R , HUTANU, A , FEIER, C , BAJKO, Z , PASCU, I , (2010) INCIDENCE AND CLINICAL SIGNIFICANCE OF BINDING ANTIBODIES AND THEIR RELATIONSHIPS WITH NEUTRALIZING ANTIBODIES, BOTH INDUCED BY INTERFERON-BETA TREATMENT IN MULTIPLE SCLEROSIS PATIENTS.REVISTA ROMANA DE MEDICINA DE LABORATOR. VOL. 18. ISSUE 3. P. 39 -50 62 98% 0
9 BERTOLOTTO, A , CAPOBIANCO, M , AMATO, MP , CAPELLO, E , CAPRA, R , CENTONZE, D , DI IOIA, M , GALLO, A , GRIMALDI, L , IMBERTI, L , ET AL (2014) GUIDELINES ON THE CLINICAL USE FOR THE DETECTION OF NEUTRALIZING ANTIBODIES (NABS) TO IFN BETA IN MULTIPLE SCLEROSIS THERAPY: REPORT FROM THE ITALIAN MULTIPLE SCLEROSIS STUDY GROUP.NEUROLOGICAL SCIENCES. VOL. 35. ISSUE 2. P. 307-316 52 98% 5
10 HARTUNG, HP , HAAS, J , MEERGANS, M , TRACIK, F , ORTLER, S , (2013) INTERFERON-BETA(1B) IN MULTIPLE SCLEROSIS THERAPY. MORE THAN 20 YEARS CLINICAL EXPERIENCE.NERVENARZT. VOL. 84. ISSUE 6. P. 679 -+ 81 66% 1

Classes with closest relation at Level 1


Rank Class id link
1 26069 PSEUDO RELAPSE//ABT VASKULARE ZELLBIOL//ACTHAR R GEL
2 22413 ALEMTUZUMAB//DACLIZUMAB//MS CLIN CENT TEXAS
3 22707 MULTIPLE SCLEROSIS//SOLUBLE VASCULAR CELL ADHESION MOLECULES//GRP MULTIPLE SCLEROSIS NEUROIMMUNOL
4 702 MULTIPLE SCLEROSIS//NEUROIMAGING UNIT//NMR UNIT
5 14186 GLATIRAMER ACETATE//PROTECTIVE AUTOIMMUNITY//COPOLYMER 1
6 1796 MULTIPLE SCLEROSIS//KINESIOL COMMUNITY HLTH//MULTIPLE SCLEROSIS JOURNAL
7 3080 MULTIPLE SCLEROSIS//MULTIPLE SCLEROSIS JOURNAL//NORWEGIAN MULTIPLE SCLEROSIS COMPETENCE
8 19797 UCLA MULTIPLE SCLEROSIS PROGRAM//POSTPARTUM ACTIVATION//MULTIPLE SCLEROSIS
9 22994 DIMETHYL FUMARATE//FUMARIC ACID ESTERS//MONOMETHYL FUMARATE
10 26412 LINOMIDE//LAQUINIMOD//TASQUINIMOD

Go to start page